New hope for lung cancer patients when standard drugs fail
NCT ID NCT04001777
Summary
This early-stage study is testing whether adding an experimental drug called APG-1252 to an existing lung cancer medication (osimertinib) is safe and might help control tumors that have started growing again. The trial will enroll about 80 adults with advanced non-small cell lung cancer that has an EGFR mutation and has progressed despite previous treatments. Researchers will first find the safest dose of the combination, then see if it can shrink tumors in patients whose cancer has become resistant to current therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
-
Henan Provincial people's Hospital
Zhengzhou, Henan, China
-
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
-
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.